

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 00719)

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (“**Directors**”) of Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries from time to time, the “**Group**”) announces that:

The Board has resolved to propose Mr. Liu Weimin (“**Mr. Liu**”) as a candidate to be appointed as an executive Director, subject to the approval of the shareholders of the Company (the “**Shareholders**”) at the upcoming extraordinary general meeting of the Company (the “**EGM**”) to be held on or about 10 November 2026, based on the recommendation proposed by the nomination committee of the Board.

A circular containing details of the proposed appointment of Mr. Liu as an executive Director, together with the notice of the EGM, will be despatched to the Shareholders in due course.

Proposed Appointment of Executive Director

Upon the recommendation of the nomination committee of the Board, on 9 October 2026, the Board has resolved to nominate Mr. Liu as a candidate to be appointed as an executive Director, for a proposed term of office commencing from the date of approval given by the Shareholders at the EGM (i.e. currently expected to be 10 November 2026) and ending on the expiry of the eleventh session of the Board on 21 December 2026 (the “**Proposed Term**”). Pursuant to the articles of association of the Company and the Company Law of the People's Republic of China, the appointment of Mr. Liu to the Board shall be subject to, and shall take effect upon, the obtaining of approval of the Shareholders by way of ordinary resolution at the EGM.

Mr. Liu Weimin (劉偉民), aged 47, is a senior economist. He graduated from Shandong University with a bachelor's degree and started his career in July 2001. He previously served as Manager, Senior Manager, Deputy Director and Senior Deputy Director of the General Office (Party Committee Office, Board of Directors Office, General Manager's Office) of Hualu Holding Group Co., Ltd. (“**Hualu Group**”, the controlling shareholder (as defined in the Listing Rules) of the Company); and as the General Manager of the Enterprise Management Department (Work Safety Office, Emergency Management Office, Comprehensive Deepening Reform Leading Group Office) of Hualu Group. Mr. Liu has years of experience in enterprise management. Mr. Liu has joined the Company since September 2026 and has served as the Secretary of the Party Committee of the Company.

Upon approval by the Shareholders at the EGM, Mr. Liu will enter into a service contract with the Company in connection with his appointment as an executive Director for the Proposed Term. For the Proposed Term, Mr. Liu's monthly basic salary is proposed to be RMB 43,300. Such proposed remuneration was determined with reference to the 2026 director compensation recommendation from the remuneration committee of the Board, having taken into account, without limitation, the level of responsibility which he will undertake in his proposed role, his experience and competence required of the position, the remuneration of other executive Directors within the Group, and remuneration offered for similar positions in the industry.

It is intended that, upon expiry of the Proposed Term, Mr. Liu will be nominated for re-election as an executive Director of the twelfth session of the Board, subject to the approval of the Shareholders.

As of the date of this announcement, Mr. Liu does not hold any shares in the issued share capital of the Company.

Mr. Liu has confirmed that, save as disclosed above, as of the date of this announcement, (i) he does not have any relationship with any other Directors, senior management, substantial shareholders, or controlling shareholders of the Company; (ii) he does not hold any other major appointments or professional qualification; (iii) he does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iv) he does not hold other positions with the Company or other members of the Group; and (v) he has not held any other directorship in the last three years in any other public company the securities of which are listed on any securities market in Hong Kong or overseas.

Mr. Liu has confirmed that, save as disclosed above, there is no other information relating to the aforesaid appointment that is required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules, and the Company is not aware of any other matters in relation to his appointment that are required to be brought to the attention of the Shareholders.

GENERAL

A circular containing details of the proposed appointment of Mr. Liu as an executive Director of the Company, together with the notice of the EGM, will be despatched to the Shareholders in due course.

The Company believes that the above change to the management team of the Company will not materially affect the ordinary and usual course of business and operations of the Group.

By Order of the Board
Shandong Xinhua Pharmaceutical Company Limited
He Tongqing
Chairman

9 October 2026, Zibo, PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. He Tongqing (Chairman)

Mr. Xu Wenhui

Mr. Hou Ning

Non-executive Director:

Mr. Zhang Chengyong

Independent non-executive Directors:

Mr. Pan Guangcheng

Mr. Zhu Jianwei

Mr. Ling Peixue

Ms. Cheung Ching Ching, Daisy